Als Therapy Development FND
Watertown, MA Doing business as A L S Therapy Development Institute
- UEI
- C6KRH86RM6E6
- CAGE
- 37ZA0
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Other
- SAM.gov registration date
- Physical address
- 480 Arsenal St Suite 201, Watertown, MA 02472, USA
- Website
- als.net
- Founded
- 1999
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Industrials
- Commercial & Professional Services
- Professional Services
- Research & Consulting Services
- SIC code
- 87 Engineering & Management Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Pharmacological inhibition of TRAF2- and NCK-interacting kinase (tnik) as a treatment for ALS | Defense Health Agency | $586,740 | |
| Assessment of ALS risk factors from ALS TDI's ongoing natural history study (n = 784) | Office of Financial Resources | $2,883,469 | |
| Type i prmt inhibitor preclinical pharmacology for ALS | Defense Health Agency | $550,000 | |
| Proteomics blood-based biomarker discovery for ALS | Defense Health Agency | $281,000 | |
| Anti-CD40 ligand therapy for slowing progression and extending life in amyotrophic lateral sclerosis | Medical Command | $645,900 |
About Als Therapy Development FND
Als Therapy Development FND, doing business as A L S Therapy Development Institute, is a non-profit organization and foundation that specializes in research and development related to amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. The organization has been registered to receive federal awards since April 2005 and has a history of contributing to ALS-related research through various federal grant programs. As a recipient of multiple Project Grants from both defense and civilian agencies, the institute focuses on advancing scientific understanding and developing new treatments for ALS, which can benefit both service members and the general public.
The A L S Therapy Development Institute has received several significant federal grant awards to support its research initiatives. Recent projects include a $586,740 grant from the Defense Health Agency to investigate the pharmacological inhibition of TRAF2- and NCK-interacting kinase (TNIK) as a potential ALS treatment, and a $1,441,785 grant from the Agency for Toxic Substances and Disease Registry to assess ALS risk factors from an ongoing natural history study. Other funded research areas include preclinical pharmacology for Type I PRMT inhibitors and proteomics blood-based biomarker discovery for ALS. These grants, awarded through programs such as the Military Medical Research and Development program (CFDA 12.420) and Innovations in Applied Public Health Research program (CFDA 93.061), support the institute's work in drug development, biomarker discovery, and risk factor assessment. The organization's research contributes to the mission of the National ALS Registry and aims to improve the understanding of ALS etiology, with a focus on potential risk factors related to military service, contact sports, traumatic brain injury, neuroinflammation, environmental exposures, and infectious agents.
Quick answers
What is Als Therapy Development FND's UEI?
Als Therapy Development FND's Unique Entity ID (UEI) in SAM.gov is C6KRH86RM6E6.
What is Als Therapy Development FND's CAGE code?
Als Therapy Development FND's CAGE code is 37ZA0.
Where is Als Therapy Development FND located?
Als Therapy Development FND's physical address in SAM.gov is 480 Arsenal St Suite 201, Watertown, MA 02472, USA.
Is Als Therapy Development FND registered in SAM.gov?
Yes. Als Therapy Development FND's SAM.gov registration is active through November 21, 2026.
What is Als Therapy Development FND's most recent federal award?
Als Therapy Development FND's most recent federal grant award is Pharmacological inhibition of TRAF2- and NCK-interacting kinase (tnik) as a treatment for ALS (HT94252410258), from Defense Health Agency, on April 15, 2024.
On GovTribe
See Als Therapy Development FND's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors